Targeting the NKG2A immune pathway to treat alopecia areata
Official title: Targeting the NKG2A Pathway in Alopecia Areata
Funded at Columbia University Health Sciences · NIH-11294331 · Data updated 2026-11-12
This project will try blocking the NKG2A immune signal to reduce the immune attack on hair follicles and help people with alopecia areata regrow hair.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 6, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2026 |
| Award (this year) | $548,221 |
| NIH project number | 5R01AR084005-03 |
| Project ID | NIH-11294331 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with active alopecia areata, particularly those with recent or ongoing hair loss and autoimmune-driven forms of the condition.
✕Less likely to help
People whose hair loss is from scarring alopecia, non-autoimmune causes, or irreversible follicle destruction are unlikely to benefit from this approach.
What this research studies
Researchers found a specific type of immune cell (CD8+ T cells) that carries both activating and inhibitory signals and may drive hair loss in alopecia areata. They will study patient immune cells using single-cell sequencing, test how the NKG2A pathway affects those cells, and use lab and mouse models to see whether changing NKG2A signaling calms the immune response. The team aims to develop or repurpose antibodies or other agents that modify NKG2A activity and examine effects on inflammation around hair follicles. Results could guide future treatments that more precisely target the immune attack causing hair loss.
Why it matters
Potential benefit: If successful, this work could reduce immune-driven hair loss and lead to targeted therapies that promote hair regrowth for people with alopecia areata.
How similar studies have gone: Related immune-targeting approaches such as JAK inhibitors have helped some patients with alopecia areata, but directly targeting NKG2A is a newer and less-tested strategy in humans.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Christiano, Angela M — Columbia University Health Sciences
- Study coordinator: Christiano, Angela M
Related research
Other NIH-funded projects on the same topics.
-
Dupilumab for hair regrowth in children with alopecia areata
This project gives dupilumab to children and teens with widespread alopecia areata, especially those with allergies or high IgE, to help their hair grow back.
-
How IL-27 affects hair loss in alopecia areata
Researchers are exploring whether the immune molecule IL-27 helps stop the immune attack that causes hair loss in people with alopecia areata.
-
Using hydrogels to treat hair loss in alopecia areata
This study is exploring a new gel treatment for people with alopecia areata, a condition that causes hair loss, to see if it can help stimulate hair regrowth in a safe and effective way.
-
Using dupilumab to treat hair loss in children with alopecia areata
This study is looking at how a medication called dupilumab can help kids with alopecia areata, a condition that causes hair loss, by encouraging hair regrowth and making sure the treatment is safe and effective for them.
-
Investigating the NKG2A pathway to treat hair loss in alopecia areata
This study is looking at alopecia areata, a condition that causes hair loss, and is exploring new ways to help by targeting certain immune cells; if you're dealing with this condition, you might have a chance to join trials testing these exciting new treatments.
-
Investigating the role of IL-27 in hair loss caused by autoimmune disease
This study is looking at how a substance called IL-27 affects the immune system in people with alopecia areata, a condition that causes hair loss, to find new ways to help treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.